JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB313000

Alexa Fluor® 568 Anti-TRAF6 antibody [EP591Y]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal TRAF6 antibody - conjugated to Alexa Fluor® 568.

View Alternative Names

RNF85, TRAF6, TNF receptor-associated factor 6, E3 ubiquitin-protein ligase TRAF6, Interleukin-1 signal transducer, RING finger protein 85, RING-type E3 ubiquitin transferase TRAF6

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EP591Y

Isotype

IgG

Conjugation

Alexa Fluor® 568

Excitation/Emission

Ex: 578nm, Em: 603nm

Carrier free

No

Applications

Target Binding Affinity, Antibody Labelling

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

This antibody is unsuitable for detecting TRAF6 in tissue lysates.

style
left-column

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TRAF6 also known as TNF receptor-associated factor 6 is an E3 ubiquitin ligase that is part of the TRAF family. It has a molecular mass of approximately 60 kDa. TRAF6 is ubiquitously expressed in many types of tissues and cells including immune cells like macrophages and dendritic cells. Its primary role is to mediate signal transduction from members of the TNF receptor and Toll-like receptor (TLR) families which it achieves through polyubiquitination of target proteins. This process facilitates the recruitment of downstream signaling components necessary for cellular responses.
Biological function summary

TRAF6 plays a critical role in regulating immune and inflammatory responses. It acts within a complex often associating with other signaling proteins such as IRAK1 and TAK1 to activate downstream kinases like IKK and JNK. These signaling pathways lead to the activation of transcription factors such as NF-kB and AP-1 which regulate the expression of genes involved in inflammation and immune responses. TRAF6 is an important modulator of adaptive and innate immunity influencing both the maturation of immune cells and the body's response to infection.

Pathways

TRAF6 significantly contributes to the NF-kB and MAPK signaling pathways. In the NF-kB pathway TRAF6 mediates signal transduction following TLR engagement interacting with proteins such as MyD88 and RIP1 to drive inflammatory cytokine production. In the MAPK pathway it associates predominantly with TAK1 to facilitate the phosphorylation and activation of downstream kinases. These pathways are essential for transmitting signals from cell surface receptors to the nucleus controlling the magnitude of immune signaling and cellular stress responses.

TRAF6 has a significant association with autoimmune diseases and certain cancers. In autoimmune disorders aberrant activation of TRAF6 can lead to prolonged inflammation and detrimental immune responses. For cancers TRAF6 is linked to tumor progression and metastasis acting alongside proteins like IRAK1 and RIP1 which can further promote malignancy through chronic inflammation and immune evasion. Understanding TRAF6's role in these diseases provides insights that could lead to targeted therapeutic strategies.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

E3 ubiquitin ligase that, together with UBE2N and UBE2V1, mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains conjugated to proteins, such as ECSIT, IKBKG, IRAK1, AKT1 and AKT2 (PubMed : 11057907, PubMed : 18347055, PubMed : 19465916, PubMed : 19713527, PubMed : 31620128). Also mediates ubiquitination of free/unanchored polyubiquitin chain that leads to MAP3K7 activation (PubMed : 19675569). Leads to the activation of NF-kappa-B and JUN (PubMed : 16378096, PubMed : 17135271, PubMed : 17703191). Seems to also play a role in dendritic cells (DCs) maturation and/or activation (By similarity). Represses c-Myb-mediated transactivation, in B-lymphocytes (PubMed : 18093978, PubMed : 18758450). Adapter protein that seems to play a role in signal transduction initiated via TNF receptor, IL-1 receptor and IL-17 receptor (PubMed : 12140561, PubMed : 19825828, PubMed : 8837778). Regulates osteoclast differentiation by mediating the activation of adapter protein complex 1 (AP-1) and NF-kappa-B, in response to RANK-L stimulation (By similarity). Together with MAP3K8, mediates CD40 signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production (By similarity). Participates also in the TCR signaling by ubiquitinating LAT (PubMed : 23514740, PubMed : 25907557).
See full target information TRAF6
style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB278695

FITC Anti-Src (phospho Y416) antibody [SrcY416-C4]

Recombinant

Flow Cytometry - FITC Anti-Src (phospho Y416) antibody [SrcY416-C4] (AB278695)

  • 0
  • 0
Primary Antibodies

AB183734

Anti-GFP antibody [EPR14104]

RabMAb|Recombinant|Lab Essentials|20ul selling size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GFP antibody [EPR14104] (AB183734)

  • 5
  • 24
Primary Antibodies

AB224942

Alexa Fluor® 647 Anti-p53 antibody [E26]

RabMAb|Recombinant|KO Validated

Immunocytochemistry/ Immunofluorescence - Alexa Fluor® 647 Anti-p53 antibody [E26] (AB224942)

  • 0
  • 1
Primary Antibodies

AB75814

Anti-GSK3 beta (phospho S9) antibody [EPR2286Y]

20ul selling size|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GSK3 beta (phospho S9) antibody [EPR2286Y] (AB75814)

  • 4
  • 10

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com